Fluidigm

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regional CLIA-Certified Labs among Growing Number of Customers Expanding  SARS-CoV-2 Testing with Fluidigm Technology Regional CLIA-Certified Labs among Growing Number of Customers Expanding  SARS-CoV-2 Testing with Fluidigm Technology

ImmunoGenomics and Vero Diagnostics Providing COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform

BENSALEM, Pa.--(BUSINESS WIRE)---- $FLDM #classaction--INVESTOR ALERT: Law Offices of Howard G.

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of Fluidigm Corporation (FLDM) on Behalf of Investors

Virtual Event Showcases CyTOF Technology and Its Use in High-Parameter Suspension Mass Cytometry and Imaging Mass Cytometry

Fluidigm Announces Agenda for 9th Annual Mass Cytometry Summit

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Fluidigm Corporation (FLDM) on Behalf of Investors

Becton, Dickinson and Co.

Co-Diagnostics

Even top diagnostic test producers got hit hard in late August.

Why Shares of These 3 Coronavirus-Test Makers Saw Big Moves in August

SOUTH SAN FRANCISCO, Calif., Sept.  08, 2020  (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced progress on the Company’s Rapid Acceleration of Diagnostics (RADx) project. Fluidigm has achieved the initial milestone under its letter contract with the National Institutes of Health, National Institute of Biomedical Imaging and Bioengineering, under the agency’s Rapid Acceleration of Diagnostics (RADx) initiative. The letter contract, which established $12 million of funding available to Fluidigm prior to execution of a definitive contract, provided for initial payment to Fluidigm of approximately $11 million based on achievement of the initial test verification milestone. Fluidigm expects to receive all $12 million in funding associated with the letter contract by the end of the third quarter and is actively engaged in finalizing the definitive contract with the NIH.

Fluidigm Achieves Initial Milestone under NIH Rapid Acceleration of Diagnostics Agreement

LOS ANGELES--(BUSINESS WIRE)---- $FLDM #classaction--The Law Offices of Frank R. Cruz announces an investigation on behalf of Fluidigm Corporation ("Fluidigm" or the "Company") (NASDAQ: FLDM) investors concerning the Company’s possible violations of federal securities laws.

The Law Offices of Frank R. Cruz Announces Investigation of Fluidigm Corporation (FLDM) on Behalf of Investors

SOUTH SAN FRANCISCO, Calif., Sept.  02, 2020  (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in investor meetings and present updates regarding Fluidigm’s business strategy and financial performance at the Cantor Virtual Global Healthcare Conference.

Fluidigm to Participate at the 2020 Cantor Virtual Global Healthcare Conference

The coronavirus testing market is suddenly a lot more crowded.

Why Fluidigm Stock Plunged Today

Fulgent Genetics

The Nasdaq Composite failed to hit a record for the first time in a week.

Nasdaq Falls 40; Fulgent, Fluidigm Collapse on COVID-19 Competition

Fluidigm (FLDM) news for Wednesday concerning EUA from the FDA to test for the novel coronavirus has FLDM stock rocketing higher.
The post Fluidigm News: Why FLDM Stock Is Soaring 30% Today appeared first on InvestorPlace.

Fluidigm News: Why FLDM Stock Is Soaring 30% Today

The FDA authorized the biological research equipment maker's new coronavirus test for emergency use.

Why Fluidigm Stock Surged Today

Fluidigm Corp. (NASDAQ: FLDM) made a splash with the markets on Wednesday morning after the company announced a critical update from the U.S.

Why Fluidigm’s COVID-19 Saliva-Based Test Is a Huge Hit

Fluidigm (NASDAQ: FLDM) shares are trading higher on Wednesday after the company announced it has received emergency use authorization from the FDA for the Advanta Dx SARS-CoV-2 RT-PCR Assay, an extraction-free saliva-based test to detect nucleic acid from COVID-19.

Why Fluidigm's Stock Is Trading Higher Today

Easy-to-Administer Saliva Test for COVID-19 Available for Immediate Shipment

Fluidigm Granted FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR  Assay for COVID-19

Fluidigm (FLDM) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Fluidigm (FLDM) Looks Good: Stock Adds 8.7% in Session

Fluidigm's (FLDM) CEO Chris Linthwaite on Q2 2020 Results - Earnings Call Transcript

Investors need to pay close attention to Fluidigm (FLDM) stock based on the movements in the options market lately.

Implied Volatility Surging for Fluidigm (FLDM) Stock Options

License for De Novo Software’s FCS Express 7 Flow to be Provided to Customers Purchasing Fluidigm Helios and Hyperion Imaging Systems License for De Novo Software’s FCS Express 7 Flow to be Provided to Customers Purchasing Fluidigm Helios and Hyperion Imaging Systems

Fluidigm and De Novo Software to Offer Mass Cytometry Customers a Streamlined Solution for Data Analysis

The struggling laboratory hardware developer received a $37 million infusion to tackle the coronavirus pandemic.

Here's Why Fluidigm Soared as Much as 58.6% Today

Fluidigm among First Seven Companies to Advance in Historic and Rapidly Instituted Program to Support Development and Commercialization of Innovative COVID-19 Testing Technologies Fluidigm among First Seven Companies to Advance in Historic and Rapidly Instituted Program to Support Development and Commercialization of Innovative COVID-19 Testing Technologies

Fluidigm Selected for $37 Million Project under National Institutes of Health RADx Initiative

Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Fluidigm (FLDM) to Report a Decline in Earnings: What to Look Out for

Test Intended to    Expand Availability of COVID-19 Screening Resources in Central Ohio

GnomeDX Files for FDA Emergency Use Authorization for Rapid Turnaround Real-Time RT-PCR COVID-19 Test Utilizing the Fluidigm Biomark HD Platform

Fluidigm Is An Under The Radar Beneficiary From The Shortage Of COVID-19 Diagnostics Equipment

Tracking the Immune Response of Patients Hospitalized with COVID-19 in 10 Research Sites Across the United States

News for Fluidigm Stock (FLDM)